Management of hematological toxicities after BCMA-directed CAR-T cell therapy.

Tags

Journal: Blood cancer journal

This study evaluated whether the CAR-HEMATOTOX (CAR-HT) score can guide supportive care in multiple myeloma patients receiving BCMA-directed CAR-T therapy.

Design and population

  • • Retrospective analysis of 224 multiple myeloma patients treated 2016–2024.
  • • Patients were stratified by CAR-HT score into low (<2) and high (≥2) risk groups.

Key findings

  • • High CAR-HT scores (58% of patients) were strongly associated with more severe early immune effector cell–associated hematotoxicity (ICAHT):
    • • Higher rates of grade 3 ICAHT (45.4% vs 23.3%).
    • • Higher rates of grade 4 ICAHT (5.4% vs 1.2%; p = 0.0069).
  • • High-risk patients had significantly more non-ICAHT cytopenias:
    • • Grade ≥3 anemia: 43.1% vs 24.4% (p < 0.0001).
    • • Grade ≥3 thrombocytopenia: 50.8% vs 27.9% (p < 0.0001).
  • • High-risk patients were about seven times more likely to require both red cell and platelet transfusions (p < 0.0001), indicating a substantially higher transfusion burden.

Supportive interventions

  • • G-CSF and thrombopoietin receptor agonists were used with variable effectiveness.
  • • Stem cell boosts, used in a small subset (4%), produced rapid trilineage hematologic recovery, suggesting particular value in selected patients with prolonged or severe cytopenias.

Infections and safety

  • • Infections were more frequent in high CAR-HT patients and in those who required intensive cytopenia-directed interventions, consistent with deeper and/or more prolonged myelosuppression.

Survival outcomes

  • • No significant differences in progression-free or overall survival were observed between low and high CAR-HT groups.
  • • Use of cytopenia-directed interventions (growth factors, TPO agonists, stem cell boosts) did not negatively impact survival.

Clinical implications

  • • The CAR-HT score is a practical risk tool before BCMA CAR-T infusion that:
    • • Predicts severity of hematotoxicity and transfusion needs.
    • • Identifies patients who may require closer monitoring, earlier transfusion planning, and consideration of proactive strategies (including potential stem cell boosts).
  • • Importantly, higher hematotoxicity risk and use of supportive interventions do not appear to compromise efficacy outcomes, supporting an aggressive supportive care approach in high-risk patients.

Leave a Reply